Price | 1W % | 1M % | 3M % | 6M % | 1Y % | YTD % |
|---|---|---|---|---|---|---|
-- | -- | -- | -- | -- | -- | -- |
AI Generated Qualitative Analysis
Your time is precious, so save it. Use AI to get the most important information from the business.
Learn about Mereo BioPharma Group plc
Mereo BioPharma Group plc News
Mereo BioPharma Group plc Quantitative Score
About Mereo BioPharma Group plc
Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom and internationally. Its lead product candidate, etigilimab (OMP-313M32), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumor. The company is also developing Navicixizumab (OMP-305B83), which has completed Phase 1b clinical trials for the treatment of the late line ovarian cancer; Acumapimod (BCT-197), a p38 MAP kinase inhibitor that is in Phase II clinical trials to treat acute exacerbations of chronic obstructive pulmonary disease; and Leflutrozole (BGS-649), an oral aromatase inhibitor for the treatment of hypogonadotropic hypogonadism. In addition, it develops rare disease product candidates, including Setrusumab (BPS-804), a novel antibody for the treatment of osteogenesis imperfecta; and Alvelestat (MPH-966), an oral small molecule that is in Phase II clinical trial to treat Alpha-1 antitrypsin deficiency. The company has a collaboration with The University of Texas MD Anderson Cancer Center to evaluate anti-TIGIT therapeutic antibody candidate, etigilimab. Mereo BioPharma Group plc was incorporated in 2015 and is based in London, the United Kingdom.
Mereo BioPharma Group plc Earnings & Revenue
What’s This Company Really Worth? Find Out Instantly.
Warren Buffett’s go-to valuation method is Discounted Cash Flow (DCF). Our tool makes it effortless — no spreadsheets, just answers in a few clicks.
Mereo BioPharma Group plc Financials
Table Compare
Compare MREO metrics with: | |||
|---|---|---|---|
Earnings & Growth | MREO | None | |
EPS (TTM) YoY Growth | -- | -- | |
Revenue (TTM) YoY Growth | -- | -- | |
Valuation (TTM) | MREO | None | |
Price/Earnings Ratio | -- | -- | |
Price/Sales Ratio | -- | -- | |
Profitability & Efficiency (TTM) | MREO | None | |
Net Profit Margin | -- | -- | |
Return on Equity | -- | -- | |
Financial Health (TTM) | MREO | None | |
Debt/Assets Ratio | -- | -- | |
Assets/Liabilities Ratio | -- | -- | |
Mereo BioPharma Group plc Income
Mereo BioPharma Group plc Balance Sheet
Mereo BioPharma Group plc Cash Flow
Mereo BioPharma Group plc Financials Over Time
Analysts Rating
Strong Buy
Buy
Hold
Sell
Strong Sell
Metrics Scores
| Metrics | Score |
|---|---|
| Discounted Cash Flows | Buy |
| Return on Equity | Strong Sell |
| Return on Assets | Strong Sell |
| Debt/Equity Ratio | Buy |
| Price/Earnings Ratio | Strong Sell |
| Price/Book Ratio | Sell |
Price Targets
Disclaimer: This 3rd party analysis information is for reference only and does not constitute investment advice.
Historical Market Cap
Shares Outstanding
Mereo BioPharma Group plc Executives
| Name | Role |
|---|---|
| Dr. Denise Vera Scots-Knight Ph.D. | Co-Founder, Chief Executive Officer & Executive Director |
| Mr. Charles Edward Sermon | Co-Founder, General Counsel, Business Development & Company Secretary |
| Ms. Christine Fox CPA | Chief Financial Officer |
| Dr. Suba Krishnan | Senior Vice President of Clinical Development |
| Mr. Bo Kara | Senior Vice President and Head of Pharmaceutical Development & CMC |
| Name | Role | Gender | Date of Birth | Pay |
|---|---|---|---|---|
| Dr. Denise Vera Scots-Knight Ph.D. | Co-Founder, Chief Executive Officer & Executive Director | 1959 | 950.95K | |
| Mr. Charles Edward Sermon | Co-Founder, General Counsel, Business Development & Company Secretary | Male | 1969 | 668.87K |
| Ms. Christine Fox CPA | Chief Financial Officer | Female | 1981 | 624.45K |
| Dr. Suba Krishnan | Senior Vice President of Clinical Development | 1965 | -- | |
| Mr. Bo Kara | Senior Vice President and Head of Pharmaceutical Development & CMC | Male | -- |
Mereo BioPharma Group plc Insider Trades
| Date | 5 Feb |
| Name | Yoskowitz Marc J |
| Role | Director |
| Transaction | Acquired |
| Type | A-Award |
| Shares | 55000 |
| Date | 5 Feb |
| Name | Yoskowitz Marc J |
| Role | Director |
| Transaction | Acquired |
| Type | A-Award |
| Shares | 13719 |
| Date | 5 Feb |
| Name | PAKIANATHAN DEEPIKA |
| Role | Director |
| Transaction | Acquired |
| Type | A-Award |
| Shares | 55000 |
| Date | 5 Feb |
| Name | Bender Jeremy |
| Role | Director |
| Transaction | Acquired |
| Type | A-Award |
| Shares | 55000 |
| Date | 5 Feb |
| Name | Bender Jeremy |
| Role | Director |
| Transaction | Acquired |
| Type | A-Award |
| Shares | 16768 |
| Date | Name | Role | Transaction | Type | Shares |
|---|---|---|---|---|---|
| 5 Feb | Yoskowitz Marc J | Director | Acquired | A-Award | 55000 |
| 5 Feb | Yoskowitz Marc J | Director | Acquired | A-Award | 13719 |
| 5 Feb | PAKIANATHAN DEEPIKA | Director | Acquired | A-Award | 55000 |
| 5 Feb | Bender Jeremy | Director | Acquired | A-Award | 55000 |
| 5 Feb | Bender Jeremy | Director | Acquired | A-Award | 16768 |